CTLA4 and neoplasm: Oral supplementation with B. fragilis in germ-free mice restored the therapeutic response of anti-CTLA-4 via the induction of T helper 1 (TH1) immune responses in tumor-draining lymph nodes (LN) and the promotion of the maturation of intra-tumoral dendritic cells (DC) [37].